Franklin Street Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Franklin Street Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20,000	Closed	-$1.21M	–	161
2016 Q4	$1.21M	Sell	20,000 -9,000	-31%	-$550K	0.21%	91
2016 Q3	$1.92M	Sell	29,000 -7,050	-20%	-$441K	0.35%	80
2016 Q2	$2.01M	Sell	36,050 -1,675	-4%	-$81.4K	0.38%	74
2016 Q1	$1.27M	Buy	37,725 +23,845	+172%	+$809K	0.25%	96
2015 Q4	$626K	Buy	13,880 +700	+5%	+$30.1K	0.12%	128
2015 Q3	$521K	Sell	13,180 -1,425	-10%	-$81.1K	0.1%	137
2015 Q2	$906K	Buy	+14,605	New	+$869K	0.16%	125

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Franklin Street Advisors's ANIP Position: Q1 2017 in Review

Franklin Street Advisors sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 20,000 shares — an estimated $1.21M sold.

Franklin Street Advisors first reported a position in ANIP in Q2 2015 and held it in 7 quarters. The position peaked at $2.01M in Q2 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

Franklin Street Advisors reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Franklin Street Advisors sold 20,000 ANI Pharmaceuticals shares in Q1 2017, an estimated $1.21M.
Franklin Street Advisors first reported a position in ANI Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Franklin Street Advisors's ANI Pharmaceuticals position peaked at $2.01M in Q2 2016.
158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Franklin Street Advisors's 13F filing for Q1 2017, filed 4 Apr 2017.